LU87977A1 - Traitement de maladies associees aux infections du vih - Google Patents

Traitement de maladies associees aux infections du vih

Info

Publication number
LU87977A1
LU87977A1 LU87977A LU87977A LU87977A1 LU 87977 A1 LU87977 A1 LU 87977A1 LU 87977 A LU87977 A LU 87977A LU 87977 A LU87977 A LU 87977A LU 87977 A1 LU87977 A1 LU 87977A1
Authority
LU
Luxembourg
Prior art keywords
treatment
diseases associated
hiv infections
hiv
infections
Prior art date
Application number
LU87977A
Other languages
English (en)
French (fr)
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Publication of LU87977A1 publication Critical patent/LU87977A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LU87977A 1989-01-26 1991-07-17 Traitement de maladies associees aux infections du vih LU87977A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30239689A 1989-01-26 1989-01-26

Publications (1)

Publication Number Publication Date
LU87977A1 true LU87977A1 (fr) 1992-03-11

Family

ID=23167578

Family Applications (1)

Application Number Title Priority Date Filing Date
LU87977A LU87977A1 (fr) 1989-01-26 1991-07-17 Traitement de maladies associees aux infections du vih

Country Status (25)

Country Link
US (1) US5607974A (xx)
JP (1) JPH04504570A (xx)
KR (1) KR940002820B1 (xx)
AU (1) AU639686B2 (xx)
BE (1) BE1004168A3 (xx)
CA (3) CA1339070C (xx)
CH (1) CH683499A5 (xx)
DE (1) DE4090165T (xx)
DK (1) DK139191A (xx)
FR (1) FR2643557B1 (xx)
GB (1) GB2243296B (xx)
GR (1) GR900100048A (xx)
IE (1) IE62795B1 (xx)
IL (1) IL93162A (xx)
IT (1) IT1237999B (xx)
LU (1) LU87977A1 (xx)
MA (1) MA21739A1 (xx)
MX (1) MX173567B (xx)
NL (1) NL9020094A (xx)
OA (1) OA09503A (xx)
PT (1) PT92949B (xx)
SE (1) SE9101815D0 (xx)
TN (1) TNSN90009A1 (xx)
WO (1) WO1990008540A1 (xx)
ZA (1) ZA90245B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205549A (es) * 1991-09-30 1993-05-01 Jess G Thoene Metodo para el tratamiento de vih.
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
EP0600462A1 (en) * 1992-12-01 1994-06-08 Nippon Flour Mills Co., Ltd. Reverse transcriptase inhibitors and antiviral agents
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
DE4325547C2 (de) * 1993-07-29 1997-11-27 Max Planck Gesellschaft Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
EP0789565A4 (en) * 1993-10-15 1999-03-24 Jess G Thoene PREVENTION OF HIV INFECTION
US5725870A (en) * 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
US5786152A (en) * 1996-04-26 1998-07-28 Amgen Inc. Methods of inhibiting syp binding to a CTLA-4 receptor
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
TW517089B (en) 1996-09-03 2003-01-11 Res Dev Foundation Assessment of intracellular cysteine and glutathione concentrations
JP4578578B2 (ja) * 1997-01-13 2010-11-10 エモリー、ユニバーシティ インフルエンザ感染の治療用化合物及びそれらの組み合わせ
US6331610B1 (en) * 1997-04-25 2001-12-18 Metatron, Inc. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
US6020205A (en) * 1998-04-10 2000-02-01 Immunosciences Lab, Inc. Determination of intracellular antioxidant levels
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
US20050070607A1 (en) * 2003-08-19 2005-03-31 James Andrus N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
JP5027512B2 (ja) 2003-11-14 2012-09-19 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫調節法
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20070053970A1 (en) * 2005-05-25 2007-03-08 Guilford F T Liposomal formulation for oral administration of glutathione (reduced) and/or methylcobalamine for diseases related to glutathione deficiency and deficiency of the methionine remethylation pathway

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) * 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US4879370A (en) * 1983-12-02 1989-11-07 Cornell Research Foundation, Inc. Glutathione delivery system
US4767785A (en) * 1984-01-18 1988-08-30 Michael Georgieff Hypocaloric preparation and intravenous method for hypocaloric treatment of patients
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
DE3707127C2 (de) * 1987-03-05 1996-06-20 Zambon Spa Verwendung von Methionin zur Behandlung von Immun-Schwächeerkrankungen bei Virusinfektionen und/oder bei Tumorerkrankungen
DE3812008A1 (de) * 1987-04-10 1988-10-20 Pfrimmer Pharma Verwendung von l-(-)-thiazolidin-4-carbonsaeure als cysteinquelle bei gestoerter cysteinsynthese
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
DE3906671A1 (de) * 1989-03-02 1990-09-06 Wulf Prof Dr Droege Orales, magenvertraegliches n-acetylcysteinpraeparat hoher dosierung

Also Published As

Publication number Publication date
OA09503A (en) 1992-11-15
PT92949A (pt) 1990-07-31
KR910700045A (ko) 1991-03-13
MX173567B (es) 1994-03-16
IL93162A0 (en) 1990-11-05
IE900073L (en) 1990-07-26
GB2243296B (en) 1992-10-21
GB2243296A (en) 1991-10-30
CA2045180A1 (en) 1990-07-27
CH683499A5 (it) 1994-03-31
CA1339070C (en) 1997-07-29
JPH04504570A (ja) 1992-08-13
WO1990008540A1 (en) 1990-08-09
GR900100048A (el) 1991-06-07
IE62795B1 (en) 1995-03-08
SE9101815L (sv) 1991-06-13
MA21739A1 (fr) 1990-10-01
FR2643557B1 (fr) 1995-02-03
AU4969490A (en) 1990-08-24
ZA90245B (en) 1990-10-31
NL9020094A (nl) 1991-10-01
AU639686B2 (en) 1993-08-05
PT92949B (pt) 1995-12-29
US5607974A (en) 1997-03-04
IT9019141A1 (it) 1991-07-24
DK139191D0 (da) 1991-07-25
DK139191A (da) 1991-07-25
IT9019141A0 (it) 1990-01-24
IL93162A (en) 1995-03-15
TNSN90009A1 (fr) 1991-03-05
BE1004168A3 (fr) 1992-10-06
CA1339256C (en) 1997-08-12
KR940002820B1 (ko) 1994-04-04
GB9112420D0 (en) 1991-07-31
SE9101815D0 (sv) 1991-06-13
DE4090165T (xx) 1991-11-21
FR2643557A1 (fr) 1990-08-31
IT1237999B (it) 1993-06-21

Similar Documents

Publication Publication Date Title
LU87977A1 (fr) Traitement de maladies associees aux infections du vih
NO894296D0 (no) Fremgangsmaate for behandling av leddgikt og betennelsessykdommer.
BE884917A (fr) Agent pour le traitement de theilerioses et son application
PT88684A (pt) Metodo de tratamento fosfatidilico de doencas virais
DE3750934T2 (de) Behandlung von nicht-Akne-entzündlichen und -infektiösen Hautkrankheiten.
EP0506893A4 (en) Diagnosis and treatment of diseases
ES2025287B3 (es) Hilos elasticos compuestos de hilos ceramicos debiles.
FR2332029A1 (fr) Gel de traitement de l'air
FR2644373B1 (fr) Machine de traitement de dechets
BE859851A (fr) Traitement d'infections bacteriennes
BR8807280A (pt) Tratamento de membranas permeaveis
BR9003055A (pt) Processo de desodorizacao de azeites e gorduras
FR2694384B1 (fr) Traitement de la surface de réfractaires.
DE69004451D1 (de) Prophylaxe und Behandlung von Herpesvirus-Infektionen.
MA21981A1 (fr) Procede de vieillissement accelere et de traitement des rhyzomes d'iris .
FR2630910B1 (fr) Table de traitement therapeutique
FR2614203B1 (fr) Composition pharmaceutique pour le traitement des maladies de la peau et son procede de preparation.
FR2604389B1 (fr) Traitement de filaments et de cables pous carcasse de pneu
FR2600256B1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
IT8948660A0 (it) Farmaco attivo nel ripristino della plasticita' neuronale
BE853603A (fr) Agent de prophylaxie et de traitement de la gastroenterite
EP0491873A4 (en) Therapeutic compositions; methods for treatment of hiv infections
FR2598082B1 (fr) Agent prophylactique et therapeutique de traitement de desordres hepatiques
BE869248A (fr) Compositions pharmaceutiques pour le traitement de l'hyperglucagonemie et/ou de l'hyperglycemie
FR2645020B1 (fr) Medicament pour le traitement des maladies infectieuses dues aux retrovirus ainsi que pour le traitement des tumeurs